orforglipron vs Pegloxenatide (Fulaimei)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

orforglipron · Foundayo

Marketed by Eli Lilly and partners

Phase 3 in Type 2 Diabetessmall molecule
Partial signal

NCT05803421 · Phase 3 · completed

ACHIEVE-4 was a randomized, open-label, event-driven Phase 3 trial. It assigned 2,749 adults with type 2 diabetes, obesity or overweight and established cardiovascular or chronic kidney disease to oral orforglipron or injected insulin glargine once daily. The primary endpoint was time to the first major cardiovascular event, and orforglipron had to be shown non-inferior to insulin glargine, with the upper limit of the 95% confidence interval for the hazard ratio below 1.8. Over a median of 2 years, events occurred in 4.2% of orforglipron patients and 5.0% of insulin glargine patients (hazard ratio 0.84, 95% CI 0.59 to 1.20), so non-inferiority was shown and the trial met its primary endpoint. The figures come from the peer-reviewed paper in The Lancet.

Next expected readout: May 2027 · NCT07613307 (registry estimate)

Reported efficacy

Mean Percent Change from Baseline in Body Weight (Baseline, Week 72): Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001) (met)

Result source: NCT05872620

Pegloxenatide (Fulaimei)

Marketed by Hansoh Pharmaceutical Group and partners

Phase 3 in Type 2 Diabetespeptide
Reliable signal

NCT02477969 · Phase 3 · status unknown

This was a randomized, triple-blind, placebo-controlled trial with 587 participants, testing PEX168 against placebo, both added to metformin, using change in HbA1c as the primary measure. A published report of the trial's results describes the primary endpoint as met, with substantially more PEX168 patients than placebo patients reaching HbA1c targets at 24 weeks.

Reported efficacy

HbA1c (Baseline to Week24): Phase 3b add-on-to-metformin trial: proportion achieving HbA1c <7.0% at week 24 was 37.4% (100μg) and 40.6% (200μg) vs 16.8% (placebo). (met)

Result source: NCT02477969

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointorforglipronPegloxenatide (Fulaimei)
HbA1c, change-1.4% vs -0.1%−1.3 vs placebo36 mg · wk 40 · n 141NCT05971940
14 other results
  • -1.6% vs -0.1% 12 mg · wk 40 · n 137 · Phase 3 · primary NCT05971940
  • -1.3% vs -0.1% 3 mg · wk 40 · n 143 · Phase 3 · primary NCT05971940
  • -2.0% vs -0.4% 36 mg · wk 26 · n 57 · Phase 2 · primary NCT05048719
  • -1.9% vs -0.4% 12 mg · wk 26 · n 49 · Phase 2 · primary NCT05048719
  • -1.2% vs -0.4% 3 mg · wk 26 · n 46 · Phase 2 · primary NCT05048719
  • -2.1% vs -0.4% 45 mg · wk 26 · n 58 · Phase 2 · primary NCT05048719
  • -1.8% vs -0.4% 24 mg · wk 26 · n 42 · Phase 2 · primary NCT05048719
  • -2.0% vs -1.1% 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • -1.9% vs -1.1% 12 mg · wk 26 · n 49 · Phase 2 · secondary NCT05048719
  • -1.2% vs -1.1% 3 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
  • -2.1% vs -1.1% 45 mg · wk 26 · n 58 · Phase 2 · secondary NCT05048719
  • -1.8% vs -1.1% 24 mg · wk 26 · n 42 · Phase 2 · secondary NCT05048719
  • -1.7% vs -0.5% orforglipron 17.2 mg · wk 72 · Phase 3 · primary NCT05872620
  • 1.7% vs 0.8% wk 40 · Phase 3 · primary NCT06192108
—Not reported
Body weight, change (kg)-7.3 vs -1.3−6 vs placebo36 mg · wk 40 · n 141NCT05971940
7 other results
  • -5.5 vs -1.3 12 mg · wk 40 · n 137 · Phase 3 · secondary NCT05971940
  • -4.4 vs -1.3 3 mg · wk 40 · n 143 · Phase 3 · secondary NCT05971940
  • -9.5 vs -2.2 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • -6.5 vs -2.2 12 mg · wk 26 · n 53 · Phase 2 · secondary NCT05048719
  • -3.7 vs -2.2 3 mg · wk 26 · n 50 · Phase 2 · secondary NCT05048719
  • -10.1 vs -2.2 45 mg · wk 26 · n 62 · Phase 2 · secondary NCT05048719
  • -9.7 vs -2.2 24 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
—Not reported
HbA1c below 7%79.0% vs 37.1%+41.9 vs placebo36 mg · wk 40 · n 119NCT05971940
7 other results
  • 81.3% vs 37.1% 12 mg · wk 40 · n 112 · Phase 3 · secondary NCT05971940
  • 78.2% vs 37.1% 3 mg · wk 40 · n 119 · Phase 3 · secondary NCT05971940
  • 92.8% vs 24.3% 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • 78.9% vs 24.3% 12 mg · wk 26 · n 49 · Phase 2 · secondary NCT05048719
  • 65.2% vs 24.3% 3 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
  • 95.8% vs 24.3% 45 mg · wk 26 · n 58 · Phase 2 · secondary NCT05048719
  • 91.2% vs 24.3% 24 mg · wk 26 · n 42 · Phase 2 · secondary NCT05048719
—Not reported
Fasting plasma glucose, change-2.0 vs -1.1−0.9 vs placebo3/6/12/21 mg QD · wk 12 · n 7NCT04426474
4 other results
  • -3 vs -1.1 3/6/9 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
  • -2.9 vs -1.1 3/6/12/15 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
  • -2.4 vs -1.1 3/6/12/21/27 mg QD · wk 12 · n 8 · Phase 1 · secondary NCT04426474
  • -2.3 vs -1.1 3/6/9/21/36/45 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
—Not reported
3-point MACE (% with event)—Not posted · NCT05803421—Not reported

HbA1c, change

orforglipron
-1.4% vs -0.1%−1.3 vs placebo36 mg · wk 40 · n 141NCT05971940
14 other results
  • -1.6% vs -0.1% 12 mg · wk 40 · n 137 · Phase 3 · primary NCT05971940
  • -1.3% vs -0.1% 3 mg · wk 40 · n 143 · Phase 3 · primary NCT05971940
  • -2.0% vs -0.4% 36 mg · wk 26 · n 57 · Phase 2 · primary NCT05048719
  • -1.9% vs -0.4% 12 mg · wk 26 · n 49 · Phase 2 · primary NCT05048719
  • -1.2% vs -0.4% 3 mg · wk 26 · n 46 · Phase 2 · primary NCT05048719
  • -2.1% vs -0.4% 45 mg · wk 26 · n 58 · Phase 2 · primary NCT05048719
  • -1.8% vs -0.4% 24 mg · wk 26 · n 42 · Phase 2 · primary NCT05048719
  • -2.0% vs -1.1% 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • -1.9% vs -1.1% 12 mg · wk 26 · n 49 · Phase 2 · secondary NCT05048719
  • -1.2% vs -1.1% 3 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
  • -2.1% vs -1.1% 45 mg · wk 26 · n 58 · Phase 2 · secondary NCT05048719
  • -1.8% vs -1.1% 24 mg · wk 26 · n 42 · Phase 2 · secondary NCT05048719
  • -1.7% vs -0.5% orforglipron 17.2 mg · wk 72 · Phase 3 · primary NCT05872620
  • 1.7% vs 0.8% wk 40 · Phase 3 · primary NCT06192108
Pegloxenatide (Fulaimei)
—Not reported

Body weight, change (kg)

orforglipron
-7.3 vs -1.3−6 vs placebo36 mg · wk 40 · n 141NCT05971940
7 other results
  • -5.5 vs -1.3 12 mg · wk 40 · n 137 · Phase 3 · secondary NCT05971940
  • -4.4 vs -1.3 3 mg · wk 40 · n 143 · Phase 3 · secondary NCT05971940
  • -9.5 vs -2.2 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • -6.5 vs -2.2 12 mg · wk 26 · n 53 · Phase 2 · secondary NCT05048719
  • -3.7 vs -2.2 3 mg · wk 26 · n 50 · Phase 2 · secondary NCT05048719
  • -10.1 vs -2.2 45 mg · wk 26 · n 62 · Phase 2 · secondary NCT05048719
  • -9.7 vs -2.2 24 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
Pegloxenatide (Fulaimei)
—Not reported

HbA1c below 7%

orforglipron
79.0% vs 37.1%+41.9 vs placebo36 mg · wk 40 · n 119NCT05971940
7 other results
  • 81.3% vs 37.1% 12 mg · wk 40 · n 112 · Phase 3 · secondary NCT05971940
  • 78.2% vs 37.1% 3 mg · wk 40 · n 119 · Phase 3 · secondary NCT05971940
  • 92.8% vs 24.3% 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • 78.9% vs 24.3% 12 mg · wk 26 · n 49 · Phase 2 · secondary NCT05048719
  • 65.2% vs 24.3% 3 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
  • 95.8% vs 24.3% 45 mg · wk 26 · n 58 · Phase 2 · secondary NCT05048719
  • 91.2% vs 24.3% 24 mg · wk 26 · n 42 · Phase 2 · secondary NCT05048719
Pegloxenatide (Fulaimei)
—Not reported

Fasting plasma glucose, change

orforglipron
-2.0 vs -1.1−0.9 vs placebo3/6/12/21 mg QD · wk 12 · n 7NCT04426474
4 other results
  • -3 vs -1.1 3/6/9 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
  • -2.9 vs -1.1 3/6/12/15 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
  • -2.4 vs -1.1 3/6/12/21/27 mg QD · wk 12 · n 8 · Phase 1 · secondary NCT04426474
  • -2.3 vs -1.1 3/6/9/21/36/45 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
Pegloxenatide (Fulaimei)
—Not reported

3-point MACE (% with event)

orforglipron
—Not posted · NCT05803421
Pegloxenatide (Fulaimei)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Pegloxenatide (Fulaimei)
Phase 3b add-on-to-metformin trial: proportion achieving HbA1c <7.0% at week 24 was 37.4% (100μg) and 40.6% (200μg) vs 16.8% (placebo). NCT02477969 · Phase 3 · design grade: strong · publication or press release
Adjusted least-squares mean HbA1c reduction from baseline at 12 weeks: -1.02% [95% CI -1.33, -0.71] (PEX168 100 μg), -1.36% [95% CI -1.68, -1.04] (PEX168 200 μg), 0.13% [95% CI -0.20, 0.45] (placebo); P < 0.05. NCT01965509 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result
Phase 3a monotherapy trial: HbA1c LS-mean change at week 24 was -1.02% (100μg) and -1.34% (200μg) vs -0.17% (placebo), p<0.0001. NCT02477865 · Phase 3 · design grade: strong · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. orforglipron: 4 of 4 rows · Pegloxenatide (Fulaimei): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricorforglipron
Dropout rate
6.7%36 mga
NCT06010004 · Phase 3 · registry result, not featured evidence
show 19 more results
5.2%12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
5.3%3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
3.5%36 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
8.8%12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
6.3%3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
7.4%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
11.8%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
10.7%12 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
7.8%3 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
6.5%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
9.4%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
10.6%24 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
—3 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
—2 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
10%3/6/12/15 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
57.1%3/6/12/21 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
11.1%3/6/12/21/27 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9/21/36/45 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
2.2%36 mga
NCT06010004 · Phase 3 · registry result, not featured evidence
show 19 more results
4.4%12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
1.5%3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
1.4%36 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
0%12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
0.7%3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
3.7%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
3.6%12 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
2%3 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%24 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
—3 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
—2 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
10%3/6/12/15 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
35.7%3/6/12/21 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
11.1%3/6/12/21/27 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9/21/36/45 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
Serious AEs
4.5%36 mga
NCT06010004 · Phase 3 · registry result, not featured evidence
show 19 more results
2.2%12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
3%3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
2.8%36 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
5.1%12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
5.6%3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
3.7%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
2.9%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
1.8%12 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
5.9%3 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
3.1%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
10.6%24 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%3 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
0%2 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
0%3/6/12/15 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/12/21 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/12/21/27 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9/21/36/45 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
36 mga
constipation 29.1%
nausea 27.6%
nasopharyngitis 16.4%
NCT06010004 · Phase 3 · registry result, not featured evidence
show 19 more results
12 mg
constipation 30.4%
nasopharyngitis 22.2%
nausea 19.3%
NCT06010004 · Phase 3 · registry result, not featured evidence
3 mg
nasopharyngitis 17.4%
constipation 16.7%
nausea 12.9%
NCT06010004 · Phase 3 · registry result, not featured evidence
36 mg
diarrhoea 25.5% (placebo 9.4%)
diabetic retinopathy 17% (placebo 15.2%)
nausea 17% (placebo 2.2%)
NCT05971940 · Phase 3 · registry result, not featured evidence
12 mg
diarrhoea 21.2% (placebo 9.4%)
dyspepsia 21.2% (placebo 7.2%)
nausea 19% (placebo 2.2%)
NCT05971940 · Phase 3 · registry result, not featured evidence
3 mg
diarrhoea 18.9% (placebo 9.4%)
diabetic retinopathy 14.7% (placebo 15.2%)
nausea 12.6% (placebo 2.2%)
NCT05971940 · Phase 3 · registry result, not featured evidence
36 mg
nausea 37% (placebo 5.5%)
vomiting 33.3% (placebo 1.8%)
diarrhoea 25.9% (placebo 7.3%)
NCT05048719 · Phase 2 · registry result, not featured evidence
36 mg
nausea 26.5% (placebo 5.5%)
vomiting 20.6% (placebo 1.8%)
eructation 8.8% (placebo 0%)
NCT05048719 · Phase 2 · registry result, not featured evidence
12 mg
nausea 37.5% (placebo 5.5%)
vomiting 21.4% (placebo 1.8%)
diarrhoea 16.1% (placebo 7.3%)
NCT05048719 · Phase 2 · registry result, not featured evidence
3 mg
nausea 23.5% (placebo 5.5%)
diarrhoea 21.6% (placebo 7.3%)
constipation 13.7% (placebo 1.8%)
NCT05048719 · Phase 2 · registry result, not featured evidence
45 mg
vomiting 35.5% (placebo 1.8%)
diarrhoea 29% (placebo 7.3%)
nausea 29% (placebo 5.5%)
NCT05048719 · Phase 2 · registry result, not featured evidence
45 mg
diarrhoea 28.1% (placebo 7.3%)
nausea 25% (placebo 5.5%)
vomiting 21.9% (placebo 1.8%)
NCT05048719 · Phase 2 · registry result, not featured evidence
24 mg
nausea 34% (placebo 5.5%)
vomiting 27.7% (placebo 1.8%)
diarrhoea 14.9% (placebo 7.3%)
NCT05048719 · Phase 2 · registry result, not featured evidence
3 mg
nausea 55.6% (placebo 25%)
constipation 33.3% (placebo 0%)
vomiting 22.2% (placebo 25%)
NCT05086445 · Phase 1 · registry result, not featured evidence
2 mg
vomiting 40% (placebo 25%)
nausea 30% (placebo 25%)
abdominal distension 20% (placebo 0%)
NCT05086445 · Phase 1 · registry result, not featured evidence
3/6/12/15 mg QD
nausea 50% (placebo 5.9%)
vomiting 50% (placebo 0%)
decreased appetite 40% (placebo 11.8%)
NCT04426474 · Phase 1 · registry result, not featured evidence
3/6/12/21 mg QD
nausea 42.9% (placebo 5.9%)
decreased appetite 28.6% (placebo 11.8%)
covid-19 21.4% (placebo 5.9%)
NCT04426474 · Phase 1 · registry result, not featured evidence
3/6/12/21/27 mg QD
decreased appetite 55.6% (placebo 11.8%)
vomiting 55.6% (placebo 0%)
nausea 33.3% (placebo 5.9%)
NCT04426474 · Phase 1 · registry result, not featured evidence
3/6/9 mg QD
vomiting 55.6% (placebo 0%)
decreased appetite 44.4% (placebo 11.8%)
nausea 44.4% (placebo 5.9%)
NCT04426474 · Phase 1 · registry result, not featured evidence
3/6/9/21/36/45 mg QD
nausea 77.8% (placebo 5.9%)
decreased appetite 66.7% (placebo 11.8%)
vomiting 55.6% (placebo 0%)
NCT04426474 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

orforglipron

HbA1c -2.13% (n=125) @ 52wk36 mg
absolute change · percentage points
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
-1.97% (n=128) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-1.71% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7% 90.82% (n=125) @ 52wk36 mg
responder rate · % of participants
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
86.11% (n=128) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
82.73% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5 84.56% (n=125) @ 52wk36 mg
responder rate · % of participants
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
76.23% (n=128) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
62.64% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 5 7 30.51% (n=125) @ 52wk36 mg
responder rate · % of participants
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
21.92% (n=128) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
7.7% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
Fasting Serum Glucose Change mg/dL -64.5 mg @ 52wk36 mg
absolute change · mg
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
-55.1 mg @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-51.7 mg @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
Weight -6.75 kg @ 52wk36 mg
absolute change · kg
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
-5.08 kg @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-1.81 kg @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
Weight Loss 5% 65.14% (n=125) @ 52wk36 mg
responder rate · % of participants
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
49.52% (n=127) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
27% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
Weight Loss 10% 37.91% (n=125) @ 52wk36 mg
responder rate · % of participants
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
24.68% (n=127) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
10.11% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
Weight Loss 15% 20.94% (n=125) @ 52wk36 mg
responder rate · % of participants
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
13.96% (n=127) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
2.79% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
Waist Circumference Change -6.5 cm @ 52wk36 mg
absolute change · cm
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
-4.6 cm @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-2.4 cm @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
BMI -2.5 kg @ 52wk36 mg
absolute change · kg
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
-1.9 kg @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-0.7 kg @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
SMBG Daily Average Change mg/dL -82.27 mg/dL @ 52wk36 mg
absolute change · mg/dL
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
-73.14 mg/dL @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-66.32 mg/dL @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence

+ 14 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: orforglipron's landscape · Pegloxenatide (Fulaimei)'s landscape